1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GlaxoSmithKline plc
  6. News
  7. Summary
    GSK   GB0009252882

GLAXOSMITHKLINE PLC

(GSK)
  Report
Real-time Estimate Cboe Europe  -  05/23 07:54:25 am EDT
1774.60 GBX   +0.60%
05/20Deutsche Bank Keeps GSK At Hold, Boosts PT
MT
05/19GLAXOSMITHKLINE : Deutsche Bank remains Neutral
MD
05/19GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
FA
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

GlaxoSmithKline : Former U.S. govt vaccine chief exits two drug developers after GSK harassment claim

03/25/2021 | 08:45am EDT
U.S. President Trump holds coronavirus response event in the Rose Garden at the White House in Washington

(Reuters) - Former Operation Warp Speed head Moncef Slaoui stepped down from his positions at two drug developers on Thursday, a day after he was dismissed from a firm controlled by GlaxoSmithKline on allegations of sexual harassment toward a GSK employee.

He resigned as chairman of U.S. vaccine developer Vaxcyte Inc following a company request and quit Centessa Pharmaceuticals, which named him chief scientific officer at the newly-formed company last month.

Slaoui did not respond to a request for comment on LinkedIn on his resignations from the two companies.

He had on Wednesday night acknowledged his dismissal from Galvani Bioelectronics, a GSK-controlled firm, and issued an apology to the employee.

"I am deeply sorry for any distress caused. I would also like to apologize to my wife and family for the pain this is causing," Slaoui said in a statement.

He was appointed the head of the U.S. government's COVID-19 vaccine development program by former U.S. President Donald Trump last year and has held top positions at several drugmakers, including GSK.

The British drugmaker said an investigation into his conduct, performed on its behalf by an independent law firm, had substantiated allegations of harassment and inappropriate contact.

The probe, which is ongoing, was the result of a letter received by GSK containing allegations of inappropriate conduct toward a company employee years ago.

Slaoui joined Vaxcyte's board in July 2017 and became chairman in May 2018. He is also a partner at investment firm Medicxi.

(Reporting by Manas Mishra in Bengaluru; Editing by Arun Koyyur)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
GLAXOSMITHKLINE PLC 0.44% 1772.2 Delayed Quote.9.80%
VAXCYTE, INC. 3.55% 26.22 Delayed Quote.10.21%
All news about GLAXOSMITHKLINE PLC
05/20Deutsche Bank Keeps GSK At Hold, Boosts PT
MT
05/19GLAXOSMITHKLINE : Deutsche Bank remains Neutral
MD
05/19GLAXOSMITHKLINE PLC : Ex-dividend day for interim dividend
FA
05/18S&P Maintains GSK's Ratings, Stable Outlook on Expected Post-Demerger Recovery
MT
05/17FTSE 100 lags European peers on strong pound
RE
05/17GlaxoSmithKline Pharmaceuticals Sees Surge in Fiscal Q4 Consolidated Net Profit
MT
05/16Glaxosmithkline Confirms It Has Changed Its Name To GSK PLC
RE
05/16GlaxoSmithKline Adopts Shortened GSK Name
MT
05/16GlaxoSmithKline plc has Changed its Name to GSK plc
CI
05/16SocGen Lifts GlaxoSmithKline's PT, Keeps Buy Rating
MT
More news
Analyst Recommendations on GLAXOSMITHKLINE PLC
More recommendations
Financials
Sales 2022 36 543 M 45 551 M 45 551 M
Net income 2022 5 289 M 6 593 M 6 593 M
Net Debt 2022 17 655 M 22 006 M 22 006 M
P/E ratio 2022 16,6x
Yield 2022 2,98%
Capitalization 89 279 M 111 B 111 B
EV / Sales 2022 2,93x
EV / Sales 2023 2,78x
Nbr of Employees 90 096
Free-Float 93,6%
Chart GLAXOSMITHKLINE PLC
Duration : Period :
GlaxoSmithKline plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GLAXOSMITHKLINE PLC
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Last Close Price 1 764,00 GBX
Average target price 1 865,77 GBX
Spread / Average Target 5,77%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Hal V. Barron Executive Director & Chief Scientific Officer
Jon Ellis VP & Head-Technology Business Development
Sector and Competitors
1st jan.Capi. (M$)
GLAXOSMITHKLINE PLC9.80%111 286
JOHNSON & JOHNSON3.45%465 705
PFIZER, INC.-11.14%294 404
ELI LILLY AND COMPANY8.19%269 013
ABBVIE INC.11.53%266 851
ROCHE HOLDING AG-15.67%266 707